DYNE 251
Alternative Names: DYNE-251Latest Information Update: 03 Oct 2025
At a glance
- Originator Dyne Therapeutics
- Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates
- Mechanism of Action Dystrophin expression stimulants; Gene silencing
-
Orphan Drug Status
Yes - Duchenne muscular dystrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 29 Sep 2025 DYNE 251 receives Orphan Drug status for Duchenne muscular dystrophy in Japan
- 04 Aug 2025 DYNE 251 receives Breakthrough Therapy status for Duchenne muscular dystrophy in USA
- 04 Aug 2025 Dyne Therapeutics continues to pursue approval pathways outside of the USA for DYNE 251 in patients with Duchenne muscular dystrophy with a confirmed mutation amenable to exon 51 skipping